Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer

Xiaoping Wang; Li Zhao; Xingzhi Song; Xiaogang Wu; Savitri Krishnamurthy; Takashi Semba; Shan Shao; Mark Knafl; Larry W. Coffer; Angela Alexander; Anita Vines; Swetha Bopparaju; Wendy A. Woodward; Randy Chu; Jianhua Zhang; Clinton Yam; Lenora W. M. Loo; Azadeh Nasrazadani; Le-Petross Huong; Scott E. Woodman; Andrew Futreal; Rare Tumor Initiative Team; Debu Tripathy; Naoto T. Ueno

doi:10.1038/s41698-024-00729-0

npj Precision Oncology (Nov 2024)

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer

Xiaoping Wang,
Li Zhao,
Xingzhi Song,
Xiaogang Wu,
Savitri Krishnamurthy,
Takashi Semba,
Shan Shao,
Mark Knafl,
Larry W. Coffer,
Angela Alexander,
Anita Vines,
Swetha Bopparaju,
Wendy A. Woodward,
Randy Chu,
Jianhua Zhang,
Clinton Yam,
Lenora W. M. Loo,
Azadeh Nasrazadani,
Le-Petross Huong,
Scott E. Woodman,
Andrew Futreal,
Rare Tumor Initiative Team,
Debu Tripathy,
Naoto T. Ueno

Affiliations

Xiaoping Wang: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Li Zhao: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Xingzhi Song: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Xiaogang Wu: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Savitri Krishnamurthy: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Takashi Semba: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Shan Shao: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Mark Knafl: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Larry W. Coffer: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Angela Alexander: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Anita Vines: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Swetha Bopparaju: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Wendy A. Woodward: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Randy Chu: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Jianhua Zhang: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Clinton Yam: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Lenora W. M. Loo: University of Hawai’i Cancer Center
Azadeh Nasrazadani: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Le-Petross Huong: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Scott E. Woodman: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Andrew Futreal: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Rare Tumor Initiative Team
Debu Tripathy: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Naoto T. Ueno: Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center

DOI: https://doi.org/10.1038/s41698-024-00729-0
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Triple-negative inflammatory breast cancer (TN-IBC) is the most aggressive type of breast cancer, yet its defining genomic, molecular, and immunological features remain largely unknown. In this study, we performed the largest and most comprehensive genomic and transcriptomic analyses of prospectively collected TN-IBC patient samples from a phase II clinical trial (ClinicalTrials.gov, NCT02876107, registered on August 22, 2016) and compared them to similarly analyzed stage III TN-non-IBC patient samples (ClinicalTrials.gov, NCT02276443, registered on October 21, 2014). We found that TN-IBC tumors have distinctive genomic, molecular, and immunological characteristics, including a lower tumor mutation load than TN-non-IBC, and an association of immunosuppressive tumor-infiltrating immune components with an unfavorable response to neoadjuvant chemotherapy. To our knowledge, this is the only study in which TN-IBC and TN-non-IBC samples were collected prospectively. Our analysis improves the understanding of the molecular landscape of the most aggressive subtype of breast cancer. Further studies are needed to discover novel prognostic biomarkers and druggable targets for TN-IBC.

Published in npj Precision Oncology

ISSN: 2397-768X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.nature.com/npjprecisiononcology/

About the journal